



Medicaid Prescribed Drug Program Spending Control Initiatives

**For the Quarter
January 1, 2014 through
March 31, 2014**

*Report to the Florida Legislature
September 2014*



**Medicaid Prescribed Drug Spending Control Program Initiatives
January 2014 – March 2014**

Table of Contents

Purpose of Report 1

Executive Summary..... 2

Pharmacy Appropriations and Spending for Quarter Three (January through March)
of State Fiscal Year 2013-2014 4

Claim Details 5

Brand and Generic Drug Costs and Utilization 5

Prescription Spending Trends..... 7

Fee-for-Service Caseload and Retail Prescription Costs..... 7

Manufacturer Rebates Reduce Net Cost of Drugs to State 7

Medicaid Fee-for-Service Prescribed Drug Program Ongoing Cost Controls 8

Cost-Effective Medicaid Preferred Drug List (PDL) 8

Preferred Drug List Adherence – PDL Products Share of Florida Medicaid Market 8

Rebate Collection Productivity 9

Prior Authorization of Specific Drugs..... 9

Medication Therapy Management 9

Medication Therapy Management..... 9

Behavioral Pharmacy Management Program..... 10

Recipient Pharmacy Lock-in Program..... 10

MEDS-AD Waiver..... 10

Report Conclusion 11

**Medicaid Prescribed Drug Spending Control Program Initiatives
January 2014 – March 2014**

Purpose of Report

Per section 409.912(37)(c), Florida Statutes, the Agency for Health Care Administration (Agency) shall submit quarterly reports to the Governor, the President of the Senate, and the Speaker of the House of Representatives which must include, but need not be limited to, the progress made in implementing this subsection and its effect on Medicaid prescribed drug expenditures. This report includes data for the third quarter of state fiscal year 2013-2014, from January 1, 2014 through March 31, 2014.

Medicaid Prescribed Drug Spending Control Program Initiatives January 2014 – March 2014

Executive Summary

Requirements of section 409.912(37)(a), F.S., relating to cost-effective purchasing of health care and the prescribed drug spending control program have been fully implemented. Generic utilization is approximately 75 percent of all Fee-for-Service prescription claims. During the third quarter of state fiscal year 2013-2014, approximately 25 percent of Medicaid recipients utilized the pharmacy benefit in a given month. While the Average Retail Price per prescription of \$96.02 during the quarter was about 12.7 percent above estimates, and total caseload during the quarter was trending 10.9 percent above annualized estimates by the Social Services Estimating Conference, the total cost for the program was still trending 4.4 percent lower than estimated for the year due to several spending control measures.

The number of individuals who were eligible for the Medicaid fee-for-service drug program as of March 31, 2014 was 1,617,976. During the third quarter of state fiscal year 2013-2014, the program reimbursed a total of 4,115,214 pharmacy claims at a total of \$395,667,367. The price of brand drugs increased from an average of \$365.47 per brand claim in December 2013 to an average of \$397.90 in March 2014. The average number of brand claims was 0.65 per user. While brand claims accounted for only 20 percent of all claims (i.e., the total number of prescriptions), they accounted for 80 percent of the total cost.

Specific spending control measures include:

- Medicaid Pharmaceutical and Therapeutics (P&T) Committee – Created by section 409.91195, F.S., the Committee makes recommendations to the Agency for the purpose of developing and maintaining the Florida Medicaid Preferred Drug List (PDL). The Committee performs ongoing scheduled review of the PDL, with negotiated state supplemental rebates from manufacturers and continued updating of prior authorization and step therapy protocols for drugs not on the PDL. The Committee may also recommend prior authorization protocols for Medicaid-covered prescribed drugs to ensure compliance with clinical guidelines, for indications not approved in labeling, and for prevention of potential overuse, misuse, or abuse.
- Prior Authorization – Authorization prior to reimbursement for certain drugs in specific circumstances continues. Age related prior authorization has been established for certain drugs to ensure safe and appropriate prescribing. Also, Medicaid pharmacists throughout the state continue to review prior authorization requests for non-PDL approved drugs. They may make initial contact with patients who choose to receive comprehensive reviews of their drug therapies. Initiatives are in place to support the use of the Medicaid PDL.
- Behavior Health Prescribing Best Practice Guidelines – Medicaid contracts with the Florida Mental Health Institute (FMHI) at the University of South Florida to develop and disseminate best practice guidelines for behavioral health drug therapy. FMHI recommendations provide specific efforts for the different needs of adults and children, coordination of care for behavioral health drug therapy management, improved patient and provider education, compliance with drug therapies and improved outcomes.
- University of Florida Medication Therapy Management Call Center (TMCC) – Through a contract with the TMCC, trained pharmacists conduct comprehensive prescribed drug case management, which involves direct patient contact if the patient chooses to participate. This statewide Medication Therapy Management Program can help resolve medication-related and health-related problems, optimize medication use for improved patient outcomes, and promote patient self-management of medication and disease states. This in turn helps reduce clinical risk and lowers prescribed drug costs to the Medicaid program including reducing the rate of inappropriate spending on Medicaid prescription drugs.

Medicaid Prescribed Drug Spending Control Program Initiatives January 2014 – March 2014

The TMCC will also measure whether maintaining health coverage for the MEDS-AD population results in fewer institutionalizations and improved health outcomes as part of the Florida MEDS-AD demonstration waiver granted by the Centers for Medicare and Medicaid Services (federal CMS).

- Prescription Benefit Manager – The contracted prescription benefit manager vendor, Magellan Medicaid Administration (Magellan), continues to process almost 1.3 million drug claims per month for the Medicaid fee-for-service pharmacy program. The system of automated claim edits is continuously refined and improved to support safe prescribing, adherence to the Preferred Drug List, and prevention of fraud and abuse.

Additional information related to Medicaid Pharmacy Services is available online at:

<http://ahca.myflorida.com/medicaid/pharmacy.shtml>

**Medicaid Prescribed Drug Spending Control Program Initiatives
January 2014 – March 2014**

Pharmacy Appropriations and Spending for Quarter Three (January through March) of State Fiscal Year 2013-2014


Table 1 shows the state fiscal year (SFY) 2013-14 appropriations for Fee-for-Service (FFS) pharmacy services along with the appropriations from the previous state fiscal year.

Table 1 – FFS Pharmacy Services Appropriations SFY2012-2013 and SFY2013-2014

Prescribed Medicine	FY 2012-2013 Appropriation	FY 2013-2014 Appropriation
Medicaid Caseload	1,410,063	1,431,982
Medicaid Prescriptions Per Month	1,491,626	1,482,342
Medicaid Unit Cost	\$83.29	\$85.18
Medicaid Total Cost	\$1,490,904,741	\$1,515,220,381

Overall it is anticipated that Medicaid Pharmacy caseload and total costs will rise 1.6 percent during state fiscal year 2013-2014 over the previous year's appropriations. The average price per prescription is expected to increase 2.3 percent while the average number of prescriptions per month is expected to decline slightly. Figure 1 below shows the actual pharmacy expenditures for the first three quarters of state fiscal year 2013-2014 compared to appropriations.

Figure 1 – Florida Medicaid FFS Pharmacy Appropriations vs. Spending Q1-Q3 SFY2013-2014



Through the first three quarters of state fiscal year 2013-2014, the total cost for the program was 6.64 percent lower than the Social Services Estimating conference estimate used for the General Appropriations Act. While the average caseload (i.e., number of recipients receiving prescriptions) and the cost per prescription were

**Medicaid Prescribed Drug Spending Control Program Initiatives
January 2014 – March 2014**

both higher than estimated, the lower number of prescriptions overall meant that total costs were lower than predicted. The average retail price per prescription during the third quarter of \$96.06 was 12.8 percent higher than the annual estimate for retail price per prescription; for the year to date, the average retail price per prescription of \$91.50 was 7.4 percent higher than the annual estimate. The Average Caseload of 1,532,399 (in terms of Member Months) through the first three quarters of state fiscal year 2013-2014 was trending to be 7.0 percent higher than estimates; and the utilization rate as measured by the number of prescriptions was 11.0 percent lower than estimated.

A generic utilization rate of over 75 percent (see Table 2; Figure 2), extensive application of manufacturer rebates and ongoing, detailed review of the Preferred Drug List to consider removal of products when lower-cost, equally effective alternatives are available, all helped maintain efficiency in the Medicaid prescribed drug program.

Claim Details

Brand and Generic Drug Costs and Utilization

Table 2 details monthly metrics related to efficient utilization of generic products, the average cost of a brand and a generic prescription, the number of brand and generic prescriptions reimbursed, and the total amounts reimbursed for drug claims.


**Table 2 – Utilization and Payments by Prescription Drug Type, Medicaid FFS Pharmacy
Third Quarter SFY2013-2014 and Fiscal Year-to-Date**

Metric	Jan-14	Feb-14	Mar-14	Q3 SFY13-14	FY to Date
Generic Utilization	75.1%	75.4%	75.6%	75.4%	75.2%
Brand Paid/Claim	\$380.93	\$386.33	\$397.90	\$388.83	\$368.52
Generic Paid/Claim	\$21.48	\$21.38	\$21.42	\$21.43	\$20.36
Non-Drug/Comp Pd/Claim	\$60.76	\$55.48	\$46.38	\$53.56	\$48.01
Brand Claims	233,138	255,298	273,816	762,252	2,326,514
Generic Claims	861,444	966,071	1,060,821	2,888,336	8,726,510
Non-Drug Claims	1,115	1,368	1,614	4,097	12,054
Compound Claims	51,512	59,150	67,393	178,055	536,431
Brand Paid	\$88,809,084	\$98,628,597	\$108,951,808	\$296,389,489	\$857,357,652
Generic Paid	\$18,504,068	\$20,657,918	\$22,723,587	\$61,885,573	\$177,697,248
Non-Drug Paid	\$51,834	\$63,699	\$75,514	\$191,047	\$571,902
Compound Paid	\$3,145,995	\$3,293,987	\$3,125,220	\$9,565,201	\$25,758,227

During the third quarter of state fiscal year 2013-2014, 19.9 percent of claims reimbursed were for brand drug products, while these prescriptions accounted for 80.5 percent of total expenditures. For the fiscal year to date, 20.1 percent of the total prescriptions have been for brand name drugs which has accounted for 80.8 percent of the total expenditures (Figure 2). Revenue realized by the state through negotiation of drug manufacturer rebates offsets a significant percentage of the retail cost of drugs in the fee-for-service pharmacy benefit. The average paid per claim for a brand prescription during the time period was \$388.83; and the average paid per claim for a generic prescription was \$21.43.

**Medicaid Prescribed Drug Spending Control Program Initiatives
January 2014 – March 2014**

Figure 2 – Florida Medicaid FFS Pharmacy Brand Name versus Generic Utilization and Expenditures, Q1-Q3 SFY2013-2014



The top row of figures in the table below reports the overall average retail reimbursement paid for a prescription claim, prior to any rebates received from manufacturers. The “Net Paid/Claim” row is the reimbursed amount less rebates received from manufacturers based on their federal rebate agreements. The row titled “Net Net Paid/Claims” shows the reimbursed amount net of federal and state supplemental rebates paid back to the state by pharmaceutical manufacturers. Additional metrics record the retail reimbursement Per Member Per Month (PMPM) and Per User Per Month (PUPM). During the third quarter of state fiscal year 2013-2014, 25.1 percent of enrollees used the prescription drug benefit in any given month.

Table 3 – Paid, Net Paid, and Net Net Paid Per Claim, Medicaid FFS Pharmacy Third Quarter SFY2013-2014 and Fiscal Year-to-Date

Metric	Jan-14	Feb-14	Mar-14	Q3 FY13-14	FY to Date
Paid/Claim	\$96.34	\$95.65	\$96.20	\$96.06	\$91.50
Net Paid/Claim	\$47.89	\$47.55	\$47.82	\$47.75	\$45.49
Net Net Paid/Claim	\$43.77	\$43.46	\$43.71	\$43.64	\$41.57
Paid PUPM	\$308.89	\$311.74	\$320.97	\$314.19	\$307.72
Net Paid PUPM	\$153.55	\$154.97	\$159.55	\$156.18	\$152.97
Net Net Paid PUPM	\$140.35	\$141.64	\$145.83	\$142.75	\$139.82
Paid PMPM	\$72.71	\$80.26	\$83.58	\$78.95	\$79.76
Net Paid PMPM	\$36.15	\$39.90	\$41.55	\$39.25	\$39.65
Net Net Paid PMPM	\$33.04	\$36.46	\$37.97	\$35.87	\$36.24
Claims/User	3.2	3.3	3.3	3.3	3.4

**Medicaid Prescribed Drug Spending Control Program Initiatives
January 2014 – March 2014**

Prescription Spending Trends

Fee-for-Service Caseload and Retail Prescription Costs

The number of individuals who were eligible for the Medicaid fee-for-service drug program as of March 31, 2014 was 1,617,976. During the third quarter of state fiscal year 2013-2014, the program reimbursed a total of 4,115,214 pharmacy claims at a total of \$395,667,367. The price of brand drugs increased from an average of \$365.47 per brand claim in December 2013 to an average of \$397.90 in March 2014. The average number of brand claims per user was 0.65 per user. The average Net Net Paid per User was up to \$145.62 in March 2014 from \$143.79 in December 2013. The following table details some basic program monthly benchmarks and overall trends for the program through the first three quarters of state fiscal year 2013-2014.

**Table 4 – Caseload, Users, Claims, and Retail Prescription Costs, Medicaid FFS Pharmacy
Third Quarter SFY2013-2014 and Fiscal Year-to-Date**


Metric	Jan-14	Feb-14	Mar-14	Q3 SFY13-14	FY to Date*
Member-Months	1,578,088	1,701,845	1,789,197	1,689,710	1,532,399
Users	393,320	420,841	431,231	415,131	391,214
Claims	1,281,887	1,403,644	1,429,683	1,371,738	1,319,345
Paid	\$122,644,201	\$134,876,129	\$138,147,037	\$395,667,367	\$1,088,586,333

* For Q3 SFY 2013-2014 and FY to Date, Member-Months, Users, and Claims are Average per Month, while Paid is Total Paid

Manufacturer Rebates Reduce Net Cost of Drugs to State

Pharmaceutical manufacturer rebate revenue paid to the state is a significant offset to the retail cost of prescription reimbursement. The program continues to negotiate agreements for manufacturers to provide supplemental rebates, in addition to federally required rebates, for their brand drug products. These rebates reduce the total retail cost of reimbursement to community pharmacy providers and allow prescribers more choices of preferred products within therapeutic classes on the Preferred Drug List. Figure 3 illustrates the

**Figure 3 – Rebates Per Claim, Medicaid FFS Pharmacy
Quarters 1 through 3 SFY 2013-2014**




Medicaid Prescribed Drug Spending Control Program Initiatives January 2014 – March 2014

amount of the average federally required and supplemental rebates received per prescription and the proportion of the total retail drug cost that the Florida Medicaid program is able to recoup through federal rebates and additional negotiated supplemental rebates.

State general revenue accounts for only 19 percent of the total retail cost of the fee-for service drug program. The chart below illustrates the percentage of state general revenue dollars required for the state to offer the Medicaid drug benefit in the fee-for-service program after federal matching funds and manufacturer rebate revenue are received.

Figure 4 – Percentage of Final Costs by Payer, Medicaid FFS Pharmacy SFY 2013-2014



Medicaid Fee-for-Service Prescribed Drug Program Ongoing Cost Controls

Cost-Effective Medicaid Preferred Drug List (PDL)

The Florida Medicaid Preferred Drug List continues to produce significant savings of pharmacy costs since its implementation as a mandatory program in 2005. The savings are achieved two ways: 1) Through efficient prescribing protocols (cost avoidance through prior authorization and step therapy); and, 2) Through the State Supplemental Rebate Program (negotiated cash rebates from manufacturers relating to placement on the PDL).

Preferred Drug List Adherence – PDL Products Share of Florida Medicaid Market

Through aggressively negotiating supplemental rebates and favorable net pricing, the Florida Medicaid prescribed drug program is able to maintain an array of choices for prescribers within each therapeutic class on the Preferred Drug List. During the third quarter of state fiscal year 2013-2014, PDL products represented 94.2 percent of prescriptions reimbursed by Florida Medicaid for fee-for-service recipients and 82.9 percent of the total amount reimbursed. Approval for reimbursement of prescriptions for products not on the PDL may be obtained through prior authorization.

**Medicaid Prescribed Drug Spending Control Program Initiatives
January 2014 – March 2014**

Rebate Collection Productivity

The rebate collection contractor performs follow-up on all unpaid or disputed invoices and as of March 31, 2014, had achieved an overall collection percentage of 98 percent of invoiced rebates from manufacturers in the fee-for-service pharmacy program. Nonpaying manufacturers are reported to the federal Centers for Medicare and Medicaid Services. The contractor continues to refer providers who cannot or will not reverse billing errors and rebill correctly to the Agency for Health Care Administration’s Bureau of Medicaid Program Integrity.

Prior Authorization of Specific Drugs

As in all states’ Medicaid programs, authorization prior to reimbursement for certain drugs in specific circumstances continues. Response to prior authorization requests is immediate through automatic claim system edits or by the Medicaid fiscal agent’s Pharmacy Benefits Manager (Magellan Medication Administration). Magellan runs a Therapeutic Call Center which is a 24-hour toll-free request line staffed by pharmacists at all times. Approval of some specific medications requires clinical review by a Medicaid staff clinical pharmacist. These requests are handled within 24 hours. Requests are either approved, denied, or can result in a change in therapy. During the first three quarters of state fiscal year 2013-14, Florida received a total of 84,050 prior authorization requests, an average of almost 307 per day, and 9,339 per month.

The following chart details metrics related to prior authorization requests received during the first three quarters of state fiscal year 2013-2014.

**Table 5 - Pharmacy Prior Authorization Requests, Medicaid FFS
Third Quarter SFY2013-2014 and Fiscal Year-to-Date**

Metric	Jan-14	Feb-14	Mar-14	Q3 SFY13-14	FY to Date
Total PA Requests	9,635	9,251	10,066	28,952	84,050
Average Per Day	310.8	330.4	324.7	321.7	306.8
Total PA Requests Approved	8,345	7,950	8,468	24,763	71,036
% PA Requests Approved	86.6%	85.9%	84.1%	85.5%	84.5%

Medication Therapy Management

Medication Therapy Management

Section 409.912(37)(a), F.S., requires that the Agency implement a Medicaid prescription drug management system. The management system is required to rely on cooperation between physicians and pharmacists to determine appropriate practice patterns and clinical guidelines to improve the prescribing, dispensing, and use of drugs in the Medicaid program. Further, the drug management system had to be designed to improve the quality of care and prescribing practices based on best practice guidelines, improve patient adherence to medication plans, reduce clinical risk, and lower prescribed drug costs and the rate of inappropriate spending on Medicaid prescription drugs.

The statewide Medication Therapy Management (MTM) Program provides interventions that help improve prescribing, dispensing, and medication usage for recipients through population-based strategies. Participating pharmacists are trained to deliver detailed medication reviews and improve coordination of medical care for patients. In April 2011, the MTM program transitioned to a patient-centered review process in which recipients may choose to speak directly via telephone with pharmacists who have real-time access to the patients’ drug profiles and medical claim histories. Feedback from recipients who chose to participate has been measurably positive, and their self-reported understanding of and compliance with their drug therapies

Medicaid Prescribed Drug Spending Control Program Initiatives January 2014 – March 2014

has improved. The reviews are now performed through the University of Florida Medication Therapy Management Call Center.

Behavioral Pharmacy Management Program

The Florida Medicaid Drug Therapy Management Program for Behavioral Health was created by the Florida Legislature in 2005. Its purpose as stated in section 409.921(37), F.S., is to accomplish the following:

- Improve the quality of behavioral health drug prescribing;
- Improve patient adherence;
- Reduce clinical risk; and,
- Lower costs.

The Agency contracted with the Florida Mental Health Institute (FMHI) at the University of South Florida to implement this program. Initially, the focus was to slow the escalation of expenditures on mental health prescriptions. The focus of the program has broadened to include quality and safety issues, and separate specific recommendations for children and adults.

Recipient Pharmacy Lock-in Program

In October 2002, the Agency implemented a recipient lock-in program. This program improves coordination of medical care and prevents potential fraud by ensuring that at least one medical professional, the pharmacist, is aware of all the medications the recipient is receiving. Recipients who have been identified as high users and potential abusers of prescribed drugs, or who obtain prescriptions from multiple physicians, are enrolled into the lock-in program and must obtain all of their medications from a single pharmacy. The majority of recipients originally enrolled in the program now receive their prescription drug benefits through Medicare. Further, highly efficient claim system enhancements now monitor the patient's full drug profile and systematically control for overutilization and potential abuse so that the number of lock-in patients who required manual monitoring can be kept to a minimum. Due to limitations set by the Agency on controlled substances (based on number of prescriptions and their diagnoses) and the drug database for controlled substances (eForce) available to prescribers and pharmacies, the number of recipients enrolled in the lock-in program has decreased significantly. As of September 30, 2013 there were no longer any active participants in the lock-in program.

MEDS-AD Waiver

The Florida Medicaid Medications for Aged and Disabled (MEDS-AD) demonstration waiver provides Medicaid coverage for aged or disabled residents of the State of Florida with incomes at or below 88 percent of the federal poverty level and assets at or below \$5,000 for an individual or \$6,000 for a couple. Coverage is limited to those aged and disabled persons who are either receiving or eligible to receive institutional care, hospice or home and community-based services coverage, or who are not eligible for Medicare. The current MEDS-AD Waiver program was implemented to continue coverage for a group of individuals who would not have been eligible for Medicare Part D as of January 2006. This waiver is designed to delay the need for institutionalization of these vulnerable individuals by maintaining their level of care in the community longer through the provision of:

- Access to health care services; and
- High-Intensity Pharmacy Case Management services for non-institutionalized individuals.

The continued coverage, as well as the High-Intensity Pharmacy Case Management program, is designed to avoid costs of preventable hospitalizations or institutional placement that would otherwise occur in the next five

Medicaid Prescribed Drug Spending Control Program Initiatives January 2014 – March 2014

years had these vulnerable individuals been denied access to prescribed drugs and other medical services. The focus of the demonstration is to provide high-intensity pharmacy case management for enrollees who are not yet receiving institutional care.

The table below contains monthly MEDS-AD enrollment counts for the first three quarters of state fiscal year 2013-2014.

Table 6: 1115 MEDS-AD Waiver Total Enrollment by Month, July 2013 – March 2014

Jul-13	Aug-13	Sep-13	Oct-13	Nov-13	Dec-13	Jan-14	Feb-14	Mar-14
38,364	37,668	36,969	36,544	35,894	34,336	35,093	35,241	35,028

Expenditures reimbursed for recipients who were eligible for Medicaid through the MEDS-AD demonstration program totaled \$158,788,398 for the period January through March 2014. A total of \$481,028,827 was expended for the first three quarters of state fiscal year 2013-2014. Annual and cumulative expenditures remain well below the budget neutrality ceiling approved by federal CMS for the waiver.

Report Conclusion

This concludes the report of Medicaid Prescribed Drug Program Spending Control Initiatives for the third quarter of state fiscal year 2013-14.